{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000623","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.041270+00:00","generated_at":"2026-05-23T15:22:18.438249+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement","bullets":["Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.","Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.","Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.","Nasdaq continued listing is subject to compliance; company states it currently remains in compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000623","json":"https://secwatch.observer/filing/0001753926-25-000623.json","markdown":"https://secwatch.observer/filing/0001753926-25-000623.md","text":"https://secwatch.observer/filing/0001753926-25-000623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/0001753926-25-000623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/g084773_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:22:18.438249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}